CHMP recommendation brings new hope for patients Takeda has announced a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) recommending European […]
AD is the most common form of dementia, which affects over 944,000 people in the UK Researchers from the University of Sheffield’s Institute of Translational […]
Phase 3 trial indicates significant efficacy and safety for children and adolescents Teva Pharmaceutical Industries has presented positive data from its Phase 3 SPACE study, […]